Ari Zimran

Research interests

Publications

• Management goals for type 1 Gaucher disease: An expert consensus document from the European working group on Gaucher disease

  Blood Cells Molecules and Diseases · 2016 · 10.1016/j.bcmd.2016.10.008

• Gaucher disease types 1 and 3: Phenotypic characterization of large populations from the ICGG Gaucher Registry

  American Journal of Hematology · 2015 · 10.1002/ajh.24063

• Glucosylsphingosine Is a Highly Sensitive and Specific Biomarker for Primary Diagnostic and Follow-Up Monitoring in Gaucher Disease in a Non-Jewish, Caucasian Cohort of Gaucher Disease Patients

  PLoS ONE · 2013 · 10.1371/journal.pone.0079732

• Pilot study using ambroxol as a pharmacological chaperone in type 1 Gaucher disease

  Blood Cells Molecules and Diseases · 2012 · 10.1016/j.bcmd.2012.09.006

• How I treat Gaucher disease

  Blood · 2011 · 10.1182/blood-2011-04-308890

• Pivotal trial with plant cell–expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease

  Blood · 2011 · 10.1182/blood-2011-07-366955

• The incidence of Parkinsonism in patients with type 1 Gaucher disease: Data from the ICGG Gaucher Registry

  Blood Cells Molecules and Diseases · 2010 · 10.1016/j.bcmd.2010.10.006

• Phase 1/2 and extension study of velaglucerase alfa replacement therapy in adults with type 1 Gaucher disease: 48-month experience

  Blood · 2010 · 10.1182/blood-2010-02-268649

• A Plant-Derived Recombinant Human Glucocerebrosidase Enzyme—A Preclinical and Phase I Investigation

  PLoS ONE · 2009 · 10.1371/journal.pone.0004792

• Oral maintenance clinical trial with miglustat for type I Gaucher disease: switch from or combination with intravenous enzyme replacement

  Blood · 2007 · 10.1182/blood-2007-02-075960

• Effect of Enzyme Replacement Therapy With Imiglucerase on BMD in Type 1 Gaucher Disease

  Journal of Bone and Mineral Research · 2006 · 10.1359/jbmr.061004

• Increased incidence of Parkinson disease among relatives of patients with Gaucher disease

  Blood Cells Molecules and Diseases · 2006 · 10.1016/j.bcmd.2006.02.004

• Gaucher disease and cancer incidence: a study from the Gaucher Registry

  Blood · 2005 · 10.1182/blood-2004-12-4672

• Gaucher disease type 1: Revised recommendations on evaluations and monitoring for adult patients

  Seminars in Hematology · 2004 · 10.1053/j.seminhematol.2004.07.010

• Sustained therapeutic effects of oral miglustat (Zavesca, N‐butyldeoxynojirimycin, OGT 918) in type I Gaucher disease

  Journal of Inherited Metabolic Disease · 2004 · 10.1023/b:boli.0000045756.54006.17

• The role of the iminosugar N‐butyldeoxynojirimycin (miglustat) in the management of type I (non‐neuronopathic) Gaucher disease: A position statement

  Journal of Inherited Metabolic Disease · 2003 · 10.1023/a:1025902113005

• Inhibition of substrate synthesis as a strategy for glycolipid lysosomal storage disease therapy

  Journal of Inherited Metabolic Disease · 2001 · 10.1023/a:1010335505357

• Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis

  The Lancet · 2000 · https://doi.org/10.1016/s0140-6736(00)02161-9

• The Gaucher Registry

  Archives of Internal Medicine · 2000 · https://doi.org/10.1001/archinte.160.18.2835

• Occurrence of Parkinson's syndrome in type 1 Gaucher disease

  QJM · 1996 · https://doi.org/10.1093/qjmed/89.9.691

• Mutations in Jewish patients with Gaucher disease

  Blood · 1992 · 10.1182/blood.v79.7.1662.bloodjournal7971662

Current projects

No projects listed.